Navigation Links
Ardea Biosciences to Present at Two Upcoming Investor Conferences
Date:3/5/2010

and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs and risks related to the outcome of our business development activities, including collaboration or licensing agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20091104/ARDEALOGO)

SOURCE Ardea Biosciences, Inc.

Back to top

RELATED LINKS
http://www.ardeabiosciences.com

'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
2. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
3. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
4. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
5. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
6. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
7. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
8. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)...  Mytrus, a technology and services company revolutionizing clinical trials, announced ... has received approval for use by Britain,s ... first time e-Consent technology will be used in a ... Mytrus was also the first electronic informed consent ... the U.S. Food and Drug Administration in 2011. It ...
(Date:8/27/2015)... CAESAREA, Israel , August 27, 2015 ... Equity today announced a private investment in public equity ... up to $28.4 million in Itamar Medical.   ... the largest shareholder of Itamar Medical and will work ... market expansion. According to the investment agreement, ...
(Date:8/27/2015)... 27, 2015 The Elekta Linac-based ... Boston on July 9th for its ... to more fully exploit the potential of advances in ... diseases. "As an established provider of sophisticated ... assume a leadership role - in collaboration with its ...
Breaking Medicine Technology:Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 4Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 5New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... increased patient loyalty at a low cost. Personalized with practice contact information and ... existing patients. Dental offices can also incorporate Calendars into seasonal mailings, thank you ...
(Date:8/28/2015)... ... August 28, 2015 , ... Mendon, IL, home of the Adams County ... people, all for a good cause. In its second year, the “Music With A ... Best Drug Rehabilitation. The “Mission” of “Music With A Mission” is to raise money ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Louis W. ... technology innovation to transform quality and efficiency of healthcare delivery worldwide, announced the ... and aggregated before being publicly shared to document progress and inform policy in ...
(Date:8/28/2015)... Indianapolis, IN (PRWEB) , ... August 28, 2015 ... ... employee benefits advisory organization, is pleased to welcome TJS Insurance Group as its ... to employees and clients guides them and keeps them focused on their goals. ...
(Date:8/28/2015)... ... 28, 2015 , ... The Plaintiffs Steering Committee (PSC) and ... Replacement Therapy Products Liability Litigation, are in the midst of ongoing discussion regarding ... may receive for corporate employees involved in the production or marketing of AbbVie ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:WEDI's The Sullivan Institute for Healthcare Innovation Releases Gaps in Care Survey 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 2Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 3Health News:National Testosterone Lawyers Provide Testosterone Lawsuit MDL Update 4
... , , WASHINGTON , ... (National Council) is offering small emergency grants and free Mental Health ... of the devastating Haiti earthquake. , "Our thoughts are ... ones in the U.S. We commend the efforts of many agencies ...
... that launch glioblastoma multiforme, the most lethal type of brain ... scientists from The University of Texas M. D. Anderson Cancer ... the Jan. 15 issue of Clinical Cancer Research . ... also known as cancer stem cells, stifles the immune response ...
... Long-term use of low-dose versions affect women most, study finds, ... decrease bone density in young women, a new study suggests. ... years, and those on the low-dose estrogen pills appear to ... spine and whole body, according to the researchers. , "I ...
... Irritable bowel syndrome (IBS) is a common gastrointestinal ... well being. Multiple interacting mechanisms, including alterations in ... IBS aetiology. A research article to be ... World Journal of Gastroenterology addresses this question. ...
... increasing worldwide and its prognosis is very poor. ... early detection and on surgical treatment for better ... team from China retrospectively evaluated 5311 liver cancer ... December 2003. Of these, 429 (8.1%) patients were ...
... ... the new year by expanding their existing Green Bay, WI presence with the purchase ... ... technology company representing both businesses and residents has joined forces with Buildmyownsite, Inc., a ...
Cached Medicine News:Health News:Emergency Grants and Mental Health First Aid Training Available to Meet Mental Health Needs After Haiti Earthquake 2Health News:Emergency Grants and Mental Health First Aid Training Available to Meet Mental Health Needs After Haiti Earthquake 3Health News:Cancer stem cells suppress immune response against brain tumor 2Health News:Cancer stem cells suppress immune response against brain tumor 3Health News:The Pill May Decrease Bone Density 2Health News:The Pill May Decrease Bone Density 3Health News:Infinity Technology, Inc. Acquires Build My Own Site, Inc. 2
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
... Durable ergonomic chairs with concave ... support • Select options like seats, ... • Choose the BE Series for ... environments including: industry, education, laboratory, clean ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
Medicine Products: